Grundlæggende statistik
| CIK | 881464 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amylin Pharmaceuticals Inc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| February 21, 2014 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C4P(#`@;V)J#3P\+TQI;F5AF4@-C,O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R`A(,4X`$XPT@P1(.)#CY@<0'#P8F1H:#(%D&1G3B/^.D/P`!!@"S]0;D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HV,B`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``*^!`94P,@` MDN5H0!9C@6(&AAL,/`Q,]7!E+U!A9V4^/@UE;F1O8FH-3,@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9 |
|
| January 7, 2014 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``+."`94P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^W.7&F4TGN]205D<[H=#-JDK@[XLDY2,/CSZ ME.G@>5.O4FT6;'XS89G>F^5PB.$YO!+%:W&PQ0$2T?=-9T"\ |
|
| January 7, 2014 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``+.&@94P`C$+`P<#T7A,\H`!!@`+G,!2X-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B |
|
| January 7, 2014 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``).%P94P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^V@)=C+2ASM]W=E>R94%HFS#(LYHSLW-&<\Q"H,`$B!A8 M!,Q#%X,G.'"*L0@X`T9Y`#!U4V>)TANROEN05)W |
|
| February 13, 2013 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0W(#`@;V)J#3P\+TQI;F5A08`X!B7T%$28@P@TDU@)B>8*(7R#B&DAQ)I!X.8F!B9%A M'Y#%P,"(3OQG7/D'(,``Q/\+!@T*96YD8F!@X&9@8,IG``+1KPRH@!&(61@X&I#%N*&8@9&+@8M!9?%:+7Q)7\^ M&+-^2(#I,;2%T$R3X;I8&!A%LP+C`@,"XP(#8Q,BXP(#%LP M+C`@,"XP(#8Q,BXP(#EWI],OAA-&C"`\(482H=U&$:Z$)D83;C0G#1F.IUD3;XB M.G7.=X^7E2Z6>9E2S@3ADZSIT]YL=ZTQ!A!/^2=Z4(R2V?;;-T0J>BL*MO) MI/KU<*%U@C8B&&.8X!&M |
|
| November 27, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.=P94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| September 14, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`U."]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.!@94P`C$+&C"S%#, MP-#(P,W`P5<+4RG:!M71!M;%H"H"X3.J`@08`):`]8-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@,"!O M8FH-/#PO0V]N=&5N=',@ |
|
| August 21, 2012 |
Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-19700 Amylin Pharmaceuticals, LLC (Exact name of registrant as spe |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 Post-Effective Amendment to Form S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 Post-Effective Amendment to Form S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-179964 UNDER THE SECURITIES ACT OF 1933 AMYLIN PHARMACEUTICALS, LLC (Exact name of registrant as specified in its charter) Delaware 33-0266089 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO FORM S-8 Post-Effective Amendment to Form S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 20, 2012 |
- POST-EFFECTIVE AMENDMENT TO S-8 Post-Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No. |
|
| August 13, 2012 |
Exhibit 3.4 LIMITED LIABILITY COMPANY AGREEMENT OF AMYLIN PHARMACEUTICALS, LLC Dated as of August 8, 2012 LIMITED LIABILITY COMPANY AGREEMENT OF AMYLIN PHARMACEUTICALS, LLC This Limited Liability Company Agreement (this “Agreement”) of Amylin Pharmaceuticals, LLC is entered into by BMS Holdco, Inc., a Delaware corporation, as sole member (the “Managing Member”). The Managing Member hereby forms a |
|
| August 13, 2012 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AMYLIN PHARMACEUTICALS, INC. ARTICLE ONE Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMYLIN PHARMACEUTICALS, INC. ARTICLE ONE The name of the corporation is Amylin Pharmaceuticals, Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the state of Delaware is 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware 19808. The name of its regist |
|
| August 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2012 (August 8, 2012) AMYLIN PHARMACEUTICALS, LLC (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorpo |
|
| August 13, 2012 |
CERTIFICATE OF FORMATION AMYLIN PHARMACEUTICALS, LLC Certificate of Formation, dated as of August 8, 2012 Exhibit 3.3 CERTIFICATE OF FORMATION OF AMYLIN PHARMACEUTICALS, LLC This Certificate of Formation is being executed as of August 8, 2012, for the purpose of forming a limited liability company pursuant to the Delaware Limited Liability Company Act, 6 Del. C. §§ 18-101, et seq. The undersigned, being duly authorized to execute and file this Certi |
|
| August 13, 2012 |
Supplemental Indenture, dated August 8, 2012 Exhibit 4.2 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (“Supplemental Indenture”) dated as of August 8, 2012, between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY N.A. (formerly known as The Bank of New York Trust Company, N.A.), a national banking association, as trus |
|
| August 13, 2012 |
AMENDED AND RESTATED BYLAWS AMYLIN PHARMACEUTICALS, INC. A Delaware Corporation ARTICLE I Fifth Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS BYLAWS OF AMYLIN PHARMACEUTICALS, INC. A Delaware Corporation ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be located at 2711 Centerville Road, Suite 400, Wilmington Delaware 19808, in the County of New Castle. The name of the corporation’s registere |
|
| August 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) July 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 10, 2012 |
AMLN / Amylin Pharmaceuticals Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 8 Amylin Pharmaceuticals Incorporated Common Stock Cusip #032346108 Cusip #032346108 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 772,060 Item 8: 0 Item 9: 772,060 Item 11: 0.474% Item 12: HC Cusip #032346108 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 772,060 Item 8: 0 It |
|
| August 8, 2012 |
Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No.: 000-19700 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as sp |
|
| August 8, 2012 |
AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon |
|
| August 8, 2012 |
Press Release issued by Bristol-Myers Squibb Company, dated August 8, 2012 Exhibit EXA5P Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc. |
|
| August 8, 2012 |
- AMENDMENT NO.6 TO THE SCHEDULE TO Amendment No.6 to the Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 6 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 P |
|
| August 8, 2012 |
- AMENDMENT NO. 7 TO SCHEDULE 14D-9 Amendment No. 7 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 7 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share |
|
| August 3, 2012 |
SIXTH AMENDMENT TO EXENATIDE MANUFACTURING AGREEMENT Exhibit 10.2 *** Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R Sections 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. SIXTH AMENDMENT TO EXENATIDE MANUFACTURING AGREEMENT THIS SIXTH AMENDMENT to the Exenatide Manufacturing Agreement (the “Sixth Amendment”) originally made and entered into as of |
|
| August 3, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC. |
|
| August 3, 2012 |
AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT Exhibit 10.1 CONFIDENTIAL *** Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R Sections 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is entered into as of April 17, 2012 (the “Amendment Effecti |
|
| August 1, 2012 |
- AMENDMENT NO. 5 TO SCHEDULE TO SC TO-T/A 1 d389345dsctota.htm AMENDMENT NO. 5 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 5 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMM |
|
| August 1, 2012 |
PRESS RELEASE ISSUED BY BRISTOL-MYERS SQUIBB COMPANY, DATED AUGUST 1, 2012 Exhibit 99. |
|
| August 1, 2012 |
- AMENDMENT NO. 6 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 03 |
|
| July 30, 2012 |
SC 13G 1 p12-1419sc13g.htm AMYLIN PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securi |
|
| July 27, 2012 |
- AMENDMENT NO. 4 TO SCHEDULE TO Amendment No. 4 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 4 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER |
|
| July 27, 2012 |
- AMENDMENT NO. 5 TO SCHEDULE 14D-9 AMENDMENT NO. 5 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share |
|
| July 27, 2012 |
BRISTOL-MYERS SQUIBB PRICES $2.0 BILLION OF SENIOR NOTES Press Release issued by Bristol-Myers Squibb Company, dated July 26, 2012 BRISTOL-MYERS SQUIBB PRICES $2. |
|
| July 27, 2012 |
EX-99.(A)(5)(L) 2 d386485dex99a5l.htm MEMORANDUM OF UNDERSTANDING Exhibit (a)(5)(L) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE x IN RE AMYLIN PHARMACEUTICALS, INC. SHAREHOLDERS LITIGATION : : : : CONSOLIDATED C.A. No. 7673-CS x MEMORANDUM OF UNDERSTANDING WHEREAS, this Memorandum of Understanding (“MOU”) is entered into as of July 27, 2012, by and among the parties to the action captioned I |
|
| July 27, 2012 |
- AMENDMENT NO. 4 TO SCHEDULE 14D-9 SC 14D9/A 1 d386485dsc14d9a.htm AMENDMENT NO. 4 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common S |
|
| July 23, 2012 |
- AMENDMENT NO. 3 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 03 |
|
| July 23, 2012 |
Class Action Complaint dated July 20, 2012 Exhibit (a)(5)(K) Case 3:12-cv-01787-LAB-JMA Document 1 Filed 07/20/12 Page 1 of 42 WEISS & LURIE LEIGH A. |
|
| July 23, 2012 |
Exhibit (a)(5)(L) BRAMSON, PLUTZIK, MAHLER & BIRKHAEUSER, LLP Alan R. Plutzik (State Bar No. 077785) Michael S. Strimling (State Bar No. 96135) 2125 Oak Grove Road, Suite 120 Walnut Creek, CA 94598 Tel: (925) 945-0200 Fax: (925) 945-8792 LEVI & KORSINSKY LLP Joseph Levi (to be admitted pro hac vice) W. Scott Holleman (to be admitted pro hac vice) 30 Broad Street, 24th Floor New York, New York 1000 |
|
| July 23, 2012 |
- AMENDMENT NO. 3 TO SCHEDULE TO AMENDMENT NO. 3 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 3 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER |
|
| July 18, 2012 |
- AMENDMENT NO. 2 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 03 |
|
| July 18, 2012 |
- AMENDMENT NO. 2 TO SCHEDULE TO Amendment No. 2 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 2 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER |
|
| July 18, 2012 |
Class Action Complaint dated July 10, 2012 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Exhibit (a)(5)(J) FILED CIVIL BUSINESS OFFICE 8 CENTRAL DIVISION 12 JUL 10 PM 2:04 CLERK-SUPERIOR COURT SAN DIEGO COUNTY, CA Evan J. |
|
| July 18, 2012 |
EX-99.(A)(5)(H) 2 d377624dex99a5h.htm STIPULATED ORDER OF CLASS CERTIFICATION AND CASE MANAGEMENT DATED JULY 10, 2012 Exhibit (a)(5)(H) GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf ) of All Others Similarly Situated, ) ) Plaintiff, ) ) v. ) C.A. No. 7673-CS ) AMYLIN PHARMACEUTICALS, INC., PAULO ) F. COSTA, ADRIAN ADAMS, TERESA BECK, ) M. KAT |
|
| July 18, 2012 |
Amended Class Action Complaint dated July 12, 2012 Exhibit (a)(5)(I) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf of All ) Others Similarly Situated, ) ) Plaintiff, ) C. |
|
| July 17, 2012 |
- AMENDMENT NO. 1 SCHEDULE 14D-9 Amendment No. 1 Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (T |
|
| July 17, 2012 |
Town Hall Meeting Exhibit (a)(5)(E) Town Hall Meeting Bob: So to get on to the main business here today. |
|
| July 17, 2012 |
- AMENDMENT NO. 1 TO SCHEDULE TO Amendment No. 1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 1 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER |
|
| July 17, 2012 |
EX-99.(A)(5)(F) 3 d380894dex99a5f.htm AMYLIN INTEGRATION - FREQUENTLY ASKED QUESTIONS (FAQS) Exhibit (a)(5)(F) Amylin Integration – Frequently Asked Questions (FAQs) Table of Contents Click on the section below to go directly to that section. Tender Offer Leadership, Structure, Sites, Timing Integration Compensation and Benefits Miscellaneous Please review this document for answers to your frequen |
|
| July 10, 2012 |
Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc. Press Release Exhibit No. (a)(5)(B) Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc. (NEW YORK & PRINCETON, NJ, July 10, 2012) — Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN |
|
| July 10, 2012 |
Exhibit No. (a)(1)(E) Offer To Purchase For Cash All Outstanding of Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation. THE OFFER AND WITHDRAWAL RIGHTS WILL |
|
| July 10, 2012 |
Exhibit No. (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation. THE OFFER AND WITHDRAWAL RIGHTS WILL EXP |
|
| July 10, 2012 |
EX-99.(A)(1)(C) 4 d376793dex99a1c.htm NOTICE OF GUARANTEED DELIVERY Exhibit No. (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMP |
|
| July 10, 2012 |
Instruction Form to be Used with the Letter of Transmittal Exhibit No. (a)(1)(F) INSTRUCTION FORM With Respect to the Offer To Purchase For Cash All Outstanding of Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiar |
|
| July 10, 2012 |
Tender and Support Agreement Exhibit (d)(2) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 29, 2012, is by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), B&R Acquisition Company, a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), Amylin Pharmaceuticals, Inc. |
|
| July 10, 2012 |
Offer to Purchase Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC. |
|
| July 10, 2012 |
Summary Advertisement as published in the Wall Street Journal Exhibit No. (a)(1)(G) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below), dated July 10, 2012, and the related Letter of Transmittal (as defined below) and any amendments or supplements |
|
| July 10, 2012 |
EX-99.(A)(1)(I) 2 d379036dex99a1i.htm LETTER Exhibit (a)(1)(I) July 10, 2012 Dear Amylin Stockholders: We are pleased to report that Amylin Pharmaceuticals, Inc. (the “Company”) has entered into an Agreement and Plan of Merger, dated June 29, 2012 (the “Merger Agreement”), with Bristol-Myers Squibb Company (“Parent”) and B&R Acquisition Company (“Merger Sub”), a wholly-owned subsidiary of Parent, |
|
| July 10, 2012 |
Class Action Complaint dated July 3, 2012 Exhibit (a)(5)(C) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf of All ) Others Similarly Situated, ) ) Plaintiff, ) C. |
|
| July 10, 2012 |
SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities |
|
| July 10, 2012 |
SC 14D9 1 d379036dsc14d9.htm SCHEDULE 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 |
|
| July 10, 2012 |
EFiled: Jul 9 2012 8:10PM Transaction ID 45230660 Case No. 7682- Exhibit (a)(5)(D) EFiled: Jul 9 2012 8:10PM Transaction ID 45230660 Case No. 7682- IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SUSHA HALBERSTAM On Behalf of Herself and All Other Similarly Situated, Plaintiff, V. AMYLIN PHARMACEUTICALS, INC., DANIEL M. BRADBURY, PAULO F. COSTA, ADRIAN ADAMS, TERESA BECK, M. KATHLEEN BEHRENS, ALEXANDER J. DENNER, KARIN EASTHAM, JAMES R. GAVIN III, JAY S. SKYL |
|
| July 10, 2012 |
Exhibit(a)(5)(D) ROBBINS UMEDA LLP BRIAN J. ROBBINS (190264) STEPHEN J. ODDO (174828) ARSHAN AMIRI (246874) EDWARD B. GERARD (248053) JUSTIN D. RIEGER (257321) 600 B Street, Suite 1900 San Diego, CA 92101 Telephone: (619) 525-3990 Facsimile: (619) 525-3991 Attorneys for Plaintiff [Additional Counsel on Signature Page] SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SAN DIEGO DOUGLAS PETERSON, |
|
| July 10, 2012 |
EX-99.(A)(1)(B) 3 d376793dex99a1b.htm LETTER OF TRANSMITTAL Exhibit No. (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY, a Delaware corp |
|
| July 6, 2012 |
Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Sec |
|
| July 6, 2012 |
Transcript of Town Hall Meeting Exhibit 99.2 Town Hall Meeting Dan: Okay, well, welcome back. Good to see everybody again. I’m absolutely delighted to introduce to you today colleagues now from Bristol-Myers Squibb and AstraZeneca. And I’d firstly like to introduce Giovanni Caforio. Giovanni is the President of U.S. Pharmaceuticals for Bristol-Myers Squibb. And sitting right next to him is Rich Fa |
|
| July 6, 2012 |
Transcript of Town Hall Meeting Exhibit 99.1 Town Hall Meeting Dan: So everybody can hear. All right, well good morning. Very exciting day here for Amylin. As I know that you’re all aware, we announced on Friday, late Friday night, after a very long day, we announced that we are entering into a definitive merger agreement with Bristol-Myers Squibb. It’s actually part of a two-part process in that |
|
| July 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 2, 2012 (June 29, 2012) BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-079-0350 (State or Other Jurisdiction of I |
|
| July 3, 2012 |
Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AND AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 Top-Up Option 7 Article II THE MERGER 8 2.1 The Merger 8 |
|
| July 3, 2012 |
Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AND AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 Top-Up Option 7 Article II THE MERGER 8 2.1 The Merger 8 |
|
| July 3, 2012 |
Assumption Agreement Exhibit 10.1 ASSUMPTION AGREEMENT This ASSUMPTION AGREEMENT (this “Assumption Agreement”) is entered into as of June 29, 2012 (the “Effective Date”) by and between Amylin Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Amylin”) and Bristol-Myers Squibb Company, a Delaware Corporation (the “Company”). Amylin and the Company |
|
| July 3, 2012 |
Assumption Agreement Exhibit 10.1 ASSUMPTION AGREEMENT This ASSUMPTION AGREEMENT (this “Assumption Agreement”) is entered into as of June 29, 2012 (the “Effective Date”) by and between Amylin Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Amylin”) and Bristol-Myers Squibb Company, a Delaware Corporation (the “Company”). Amylin and the Company |
|
| July 3, 2012 |
Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AND AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 Top-Up Option 7 Article II THE MERGER 8 2.1 The Merger 8 |
|
| July 3, 2012 |
EX-99.1 3 d376142dex991.htm JOINT PRESS RELEASE Exhibit 99.1 Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals • Strengthens Leadership Position of Successful Alliance in Growing Area of High Unmet Medical Need • Complements Current Portfolio Creating a More Comprehensive Disease Management Platform with the Addition |
|
| July 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2012 (June 29, 2012) AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of I |
|
| July 3, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2012 (June 29, 2012) AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of I |
|
| July 2, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 2, 2012 |
Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Sec |
|
| July 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Names of Filing Persons (identifying status as offer |
|
| July 2, 2012 |
Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Names of Filing Persons (identifying sta |
|
| July 2, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) ( |
|
| July 2, 2012 |
Joint Press Release Exhibit 99.1 Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals • Strengthens Leadership Position of Successful Alliance in Growing Area of High Unmet Medical Need • Complements Current Portfolio Creating a More Comprehensive Disease Management Platform with the Addition of Novel GLP-1 Agonist Franc |
|
| July 2, 2012 |
EX-99.1 2 d375971dex991.htm JOINT PRESS RELEASE Exhibit 99.1 Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals • Strengthens Leadership Position of Successful Alliance in Growing Area of High Unmet Medical Need • Complements Current Portfolio Creating a More Comprehensive Disease Management Platform with the Addition |
|
| June 18, 2012 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) ( |
|
| June 15, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.^0RH@!&(61@X&I#% MF*&8@:&1@9N!=$DF$K1$U`=;6!=#*H!$#ZC+$"``0#3%LP(#`@-C$R(#PV,4DINE)-&G(5DELM=`YYO'4ZGU7$U M"H((1AX5YGK4W)OR<&W |
|
| June 7, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.*P94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| June 5, 2012 |
8-K 1 d363338d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction |
|
| May 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 16, 2012 |
Equity Incentive Plan. Exhibit 99.1 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN (AMENDED BY THE BOARD MARCH 6, 2012) (APPROVED BY THE STOCKHOLDERS MAY 15, 2012) 1. GENERAL. (a) The Plan is intended as the successor to and continuation of the Amylin Pharmaceuticals, Inc. 2001 Equity Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional stock awards shall be gran |
|
| May 16, 2012 |
AMYLIN PHARMACEUTICALS, INC. 2001 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED Employee Stock Purchase Plan. Exhibit 99.2 AMYLIN PHARMACEUTICALS, INC. 2001 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED 1. PURPOSE. (a) The purpose of the Plan is to provide a means by which Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of the Common Stock of the Company. (b) The Company, by means of the Plan, seeks to retain the |
|
| May 15, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (C |
|
| May 15, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d353148ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of |
|
| May 7, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC |
|
| May 7, 2012 |
***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) Exhibit 10.1 MASTER SERVICE AGREEMENT This Master Service Agreement (this “Agreement”) made as of February 1, 2012 and effective as of November 7, 2011 (the “Effective Date”) by and between Ventiv Commercial Services, LLC, a New Jersey limited liability company with offices at 500 Atrium Drive, So |
|
| May 3, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.*@94P`C$+`P<#4`0@P`+S(!)0-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3) |
|
| May 2, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.3@94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| April 26, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) |
|
| April 26, 2012 |
Press release Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Media – Alice Izzo Phone: (858) 232-9072 Email: [email protected] AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS BYDUREON, first and only weekly treatment for type 2 diabetes, launched in the U.S. San Diego, CA – Apri |
|
| April 25, 2012 |
AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon |
|
| April 12, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.4`94P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^`P*7((?` M$^"!G8802`$";0Q!<.!H]:LK=KLW=ZE11MOU7+$`7U"P[&6G M3W>R>N=UMW?O'S*\E*W,-=X+X |
|
| April 12, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.5P94P`C$+`P<#4!@@P`("D`X$-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3) |
|
| April 12, 2012 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 9, 2012 |
AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon |
|
| April 4, 2012 |
AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon |
|
| March 9, 2012 |
13,000,000 Amylin Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT Underwriting Agreement Exhibit 1.1 13,000,000 Amylin Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT March, 7, 2012 CREDIT SUISSE SECURITIES (USA) LLC, Eleven Madison Avenue, New York, N.Y. 10010-3629 Dear Sirs: 1. Introductory. Amylin Pharmaceuticals, Inc., a Delaware corporation (“Company”), agrees with Credit Suisse Securities (USA) LLC (“Credit Suisse”) to issue and sell 13,000,000 s |
|
| March 9, 2012 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-179964 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit(1) Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.001 per share 14,950,000 $16.01 $239,349,500 $27,430 (1) Estimated s |
|
| March 9, 2012 |
AMYLIN PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Media – Alice Izzo Phone: (858) 642-7272 Email: [email protected] AMYLIN PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, March 7, 2012 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is offering |
|
| March 9, 2012 |
AMYLIN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.2 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Media – Alice Izzo Phone: (858) 642-7272 Email: [email protected] AMYLIN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, March 8, 2012 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the prici |
|
| March 9, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) ( |
|
| March 7, 2012 |
S-3ASR 1 d309792ds3asr.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on March 7, 2012 Registration No. 333– SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S–3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0266089 (State of Incorporation) (I |
|
| March 7, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.<@94P`C$+`P<#4OA,\H#1!@`,0V!84-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B |
|
| March 7, 2012 |
Table of Contents The Information in this preliminary prospectus supplement is not complete and may be changed. |
|
| March 7, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.7`94P`C$+`P<#%LP(#`@-C$R(#:HR8&/P1;9>FWGTYR$B>LC+8(/?C^=[H[Z\="H,`$B!A8 M!,PS6PR>X,`IB-!L#.(HANMK$R2IM;&EF4<8XW- M''T,=/*B;?)4 |
|
| March 7, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.5`94P`C$+`P<#%LP(#`@-C$R(#:HR4&/P1;9>FWGTZR$R>LE*8(/?C^=[H[Z\="H,`$B!A8 M!,PS6PR>X,`IB-!L#.(HAIL;$QF=:6-+4TYQAJ; M.?H8Z.1E4V>) |
|
| March 7, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.3@94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| March 7, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.*`94P`C$+`P<#4PA,\H!1!@`+`L!.$-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B |
|
| March 6, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) ( |
|
| February 22, 2012 |
AMENDED AND RESTATED DEVICE AND FINISHED EQW PRODUCT MANUFACTURING AGREEMENT Amended and Restated Device and Finished EQW Product Manufacturing Agreement Exhibit 10. |
|
| February 22, 2012 |
AMENDED AND RESTATED PROMISSORY NOTE $165,000,000 San Diego, California November7, 2011 Amended and Restated Promissory Note EXEUTION VERSION Exhibit 4.10 THIS AMENDED AND RESTATED PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO AMYLIN, THAT SUCH RE |
|
| February 22, 2012 |
Security Agreement Exhibit 4.7 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXECUTION VERSION SECURITY AGREEMENT among AMYLIN PHARMACEUTICALS, INC., AMYLIN OHIO LLC, EACH OF THE OTHER GRANTORS PARTY HERETO and ELI LILLY AND COMPANY November 7, 2011 TABLE OF CONTENTS PAGE ARTIC |
|
| February 22, 2012 |
Amended and Restated Loan Agreement Exhibit 4.9 EXECUTION VERSION AMENDED AND RESTATED LOAN AGREEMENT BETWEEN AMYLIN PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY AMENDED AND RESTATED LOAN AGREEMENT THIS AMENDED AND RESTATED LOAN AGREEMENT (the “Loan Agreement”) is made as of this 7th day of November, 2011 (the “Effective Date”) by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation |
|
| February 22, 2012 |
Exhibit 10.46 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXECUTION VERSION SETTLEMENT AND TERMINATION AGREEMENT by and between AMYLIN PHARMACEUTICALS, INC. and ELI LILLY AND COMPANY November 7, 2011 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 Sec |
|
| February 22, 2012 |
SECOND AMENDMENT TO THE COMMERCIAL SUPPLY AGREEMENT Second Amendment to Commercial Supply Agreement EXHIBIT 10.45 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. SECOND AMENDMENT TO THE COMMERCIAL SUPPLY AGREEMENT This Second Amendment to the Commercial Supply Agreement dated February 14, 2005 (this “Second Amendment”), is effecti |
|
| February 22, 2012 |
AMENDED AND RESTATED EXENATIDE ONCE WEEKLY SUPPLY AGREEMENT EX-10.47 13 d260205dex1047.htm AMENDED AND RESTATED EXENATIDE ONCE WEEKLY SUPPLY AGREEMENT Exhibit 10.47 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXECUTION VERSION AMENDED AND RESTATED EXENATIDE ONCE WEEKLY SUPPLY AGREEMENT This AMENDED AND RESTATED EXENATIDE ONCE WEEKLY S |
|
| February 22, 2012 |
AMYLIN PHARMACEUTICALS, INC. SECURED PROMISSORY NOTE $1,200,000,000.00 November 7, 2011 Secured Promissory Note EXECUTION VERSION Exhibit 4.6 THIS SECURED PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO AMYLIN THAT SUCH REGISTRATION A |
|
| February 22, 2012 |
10-K 1 d260205d10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0-19 |
|
| February 22, 2012 |
Subsidiaries of Amylin Pharmaceuticals, Inc. Subsidiaries of Registrant Exhibit 21.1 Subsidiaries of Amylin Pharmaceuticals, Inc. All of the following subsidiaries are 100% owned by Amylin Pharmaceuticals, Inc. Name State or Country of Incorporation or Organization Amylin Investments LLC Delaware Amylin Ohio LLC Delaware |
|
| February 22, 2012 |
Summary Description of Named Executive Officer Oral At-Will Employment Agreement Summary Description of Named Executive Officer Oral At-Will Employment Agreement Exhibit 10. |
|
| February 22, 2012 |
C O N F I D E N T I A L EXENATIDE SUPPLY AGREEMENT Exenatide Supply Agreement EXHIBIT 10.42 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. FINAL C O N F I D E N T I A L EXENATIDE SUPPLY AGREEMENT THIS AGREEMENT effective July 31, 2007, the (“Effective Date”) is made by and between Amylin Ohio LLC., having a principal place of bu |
|
| February 22, 2012 |
Third Amendment to Amended and Restated Commercial Supply Agreement EXHIBIT 10.44 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. THIRD AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT BETWEEN AMYLIN PHARMACEUTICALS, INC. AND WOCKHARDT UK (HOLDINGS) LTD. This Third Amendment to the Amend |
|
| February 22, 2012 |
SUPPLY AGREEMENT ALKERMES, INC. AMYLIN OHIO LLC SUPPLY AGREEMENT Supply Agreement EXHIBIT 10.43 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. SUPPLY AGREEMENT BETWEEN ALKERMES, INC. AND AMYLIN OHIO LLC SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (“Agreement”) is made and entered into as of December 19, 2007 (the “Effective Date”) by and between A |
|
| February 22, 2012 |
SUBSIDIARY GUARANTEE AGREEMENT Subsidiary Guarantee Agreement Exhibit 4.8 EXECUTION VERSION SUBSIDIARY GUARANTEE AGREEMENT THIS SUBSIDIARY GUARANTEE AGREEMENT (this “Agreement”) is made as of this 7th day of November, 2011 (the “Effective Date”), by Amylin Ohio LLC, a Delaware limited liability company (“Amylin Ohio”), and each of the other parties hereto as an Additional Guarantor (as herein defined) (collectively with Amylin |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2012 |
AMLN / Amylin Pharmaceuticals Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 7 Amylin Pharmaceuticals Incorporated Common Stock Cusip #032346108 Cusip #032346108 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 1,564 Item 6: 0 Item 7: 21,924,640 Item 8: 0 Item 9: 21,924,640 Item 11: 14.988% Item 12: HC Cusip #032346108 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 21,924,64 |
|
| February 9, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation |
|
| February 6, 2012 |
Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Investors – Michael York Phone: (858) 458-8602 Email: [email protected] Media – Alice Izzo Phone: (858) 642-7272 Email: [email protected] AMYLIN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS Strategic E |
|
| February 6, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation |
|
| January 30, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation |
|
| January 30, 2012 |
Press Release Exhibit 99.1 Media contacts: Amylin – Alice Izzo Phone: (858) 642-7272 Cell: (858) 232-9072 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] FDA Approves BYDUREON™ – The First and Only Once-Weekly Treatment for Type 2 Diabetes Provides Glycemic Control in a Once-Weekly Dose SAN DIEGO and DUBLIN, I |
|
| December 7, 2011 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation |
|
| November 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2011 (November 7, 2011) AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Inc |
|
| November 8, 2011 | ||
| November 8, 2011 |
Exhibit 99.1 Contacts: Amylin - Anne Erickson (Media) Michael York (Investors) Phone: (858) 754-4443 Phone: (858) 458-8602 Email: [email protected] Email: [email protected] Lilly - Tarra Ryker (Media) Phil Johnson (Investors) Phone: (317) 332-7502 Phone: (317) 655-6874 Email: [email protected] Email: [email protected] FOR IMMEDIATE RELEASE Lilly and Amylin Mutually Agree to |
|
| October 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d235704d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number |
|
| October 28, 2011 |
AMENDMENT TO DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT EX-10.1 2 d235704dex101.htm AMENDMENT TO DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT Exhibit 10.1 Confidential AMENDMENT TO DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT THIS AMENDMENT (“Amendment”) is effective as of the 8th day of July, 2011 and is by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (“AMYLIN”), and ELI LILLY AND COMPANY, an Indiana corporation (“LILLY”). AMYL |
|
| October 20, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 20, 2011 |
Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kelley Murphy Phone: (317) 277-4607 Cell: (317) 701-4007 Email: [email protected] BYETTA? Approved for Use with Insulin Glargine in the U.S. Patients in Pivotal Study Achieved Better Glycemic Control Without Weight Gain or Increased Hypoglycemia Risk Versus Insulin |
|
| October 19, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Non-GAAP Operating Income of $13 Million Amylin Well Positioned for Anticipated Launch of BYDUREONTM in Early 2012 San Diego, CA ? October 19, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2011. ? Total revenue was $175.0 millio |
|
| October 19, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation |
|
| August 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC. |
|
| July 28, 2011 |
Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] BYDUREON? REPLY SUBMITTED TO FDA New PDUFA Action Date Expected Within 14 D |
|
| July 28, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 26, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Company Approaches Break-Even Operating Results with a 77% Improvement in Non-GAAP Operating Loss Compared to Same Period Last Year BYDUREON? Approved for Use in Europe San Diego, CA ? July 26, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended J |
|
| July 26, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 18, 2011 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| July 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032346108 (CUSIP Number) July 6, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| July 8, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (C |
|
| July 8, 2011 |
EX-99.1 2 dex991.htm PRESS RELEASE Exhibit 99.1 Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] Exenatide tQT Study Showed No Prolongati |
|
| July 5, 2011 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| July 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032346108 (CUSIP Number) June 23, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 9, 2011 | ||
| June 9, 2011 |
Exhibit 99.1 Case 3:11-cv-01061-JLS -NLS *SEALED* Document 44 Filed 06/08/11 Page 1 of 4 1 2 3 4 5 6 UNITED STATES DISTRICT COURT 7 SOUTHERN DISTRICT OF CALIFORNIA 8 9 AMYLIN PHARMACEUTICALS, INC., CASE NO. 11-CV-1061 JLS (NLS) 10 Plaintiff, ORDER: (1) VACATING vs. TEMPORARY RESTRAINING 11 ORDER; (2) DENYING PLAINTIFF AMYLIN 12 PHARMACEUTICALS, INC.?S ELI LILLY AND COMPANY, MOTION FOR PRELIMINARY |
|
| June 9, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 26, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 26, 2011 |
Case 3:11-cv-01061-JLS-NLS *SEALED* Document 14 Filed 05/23/11 Page 1 of 6 Order of the U.S. District Court Dated May 23, 2011 Exhibit 99.1 Case 3:11-cv-01061-JLS-NLS *SEALED* Document 14 Filed 05/23/11 Page 1 of 6 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA AMYLIN PHARMACEUTICALS, INC., Plaintiff, vs. ELI LILLY AND COMPANY, Defendant. CASE NO. 11CV1061 JLS (NLS) ORDER 1) GRANTING IN PART PLAINTIFF’S MOTION FOR TEMPORARY RESTRAINING ORDER AND 2) SETTING |
|
| May 25, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (C |
|
| May 23, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2011 Amylin Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or other jurisdiction of incorporation) (C |
|
| May 17, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS FILES SUIT AGAINST ELI LILLY Complaint Alleges Anticompetitive Activity and Breach of Strategic Alliance Agreements San Diego, CA ? May 16, 2011 ? Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) (?Amylin? or ?the Company?) today announced that it has filed a lawsuit against Eli Lilly and Company (NYSE: LLY) (?Lilly?) in the United States Distri |
|
| May 17, 2011 |
Financial Statements and Exhibits, Other Events 8-K 1 d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Inc |
|
| May 5, 2011 |
Exhibit 10.2 AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS? EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?) (collectively, the ?Award?) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceut |
|
| May 5, 2011 |
AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.3 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?) (collectively, the ?Award?) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceuticals, Inc. (the ?Compan |
|
| May 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 A |
|
| May 5, 2011 |
***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 Exhibit 10.4 [Amylin Letterhead] February 14, 2011 Mallinckrodt Inc 675 McDonnell Blvd. St. Louis, Missouri 63134 Attn: Tim Nieters Re: Exenatide Manufacturing Agreement between Amylin Pharmaceuticals, Inc. (?Amylin?) and Mallinckrodt Inc. (?Mallinckrodt?) effective October 1, 2003, |
|
| May 5, 2011 |
Exhibit 10.1 AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS? EQUITY INCENTIVE PLAN ADOPTED APRIL 2, 2003 APPROVED BY STOCKHOLDERS MAY 14, 2003 ORIGINAL EFFECTIVE DATE: APRIL 2, 2003 AMENDED BY THE BOARD: MARCH 16, 2009 LAST AMENDED BY THE BOARD: MARCH 1, 2011 1. PURPOSES AND RELATIONSHIP WITH THE COMPANY?S 2009 EQUITY INCENTIVE PLAN. (a) Eligible Award Recipients. The persons eligible fo |
|
| April 18, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Operational Efficiencies Drove 10% Expense Reduction, 4% Gross Margin Improvement BYDUREON? Recommended for Approval in Europe San Diego, CA ? April 18, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2011. The Company reported total |
|
| April 18, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) |
|
| April 13, 2011 |
Notice and Access Card UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 13, 2011 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* NAME OF ISSUER: Amylin Pharmaceuticals, Inc. TITLE OF CLASS OF SECURITIES: Common Stock CUSIP NUMBER: 032346108 DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: March 31, 2011 Check the appropriate box to designate the rule pursuant to which this Sc |
|
| March 24, 2011 | ||
| March 24, 2011 | ||
| March 24, 2011 | ||
| March 4, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Numb |
|
| March 3, 2011 |
DURATION-6 Top-Line Study Results Announced Exhibit 99.1 Media contacts: Amylin ? Alice Izzo Phone: (858) 642-7272 Cell: (858) 232-9072 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] DURATION-6 Top-Line Study Results Announced SAN DIEGO, INDIANAPOLIS and WALTHAM, |
|
| March 3, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 25, 2011 |
AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.51 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?) (collectively, the ?Award?) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceuticals, Inc. (the ?Compa |
|
| February 25, 2011 |
Exhibit 10.52 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 SECOND AMENDMENT TO MASTER SERVICES AGREEMENT BETWEEN AMYLIN PHARMACEUTICALS, INC. AND WOCKHARDT UK (HOLDINGS) LTD. This Second Amendment to the Amended and Restated Commercial Supply Agreement (this ?Second Amendment?) is made as of November 1, 2010 (?Effective Date?), |
|
| February 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document PART IV TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2011 |
Summary Description of Named Executive Officer Oral At-Will Employment Agreement Exhibit 10.20 Summary Description of Named Executive Officer Oral At-Will Employment Agreement With the exception of Daniel M. Bradbury, our President and Chief Executive Officer, with whom we have a written employment agreement, we maintain oral at-will employment relationships with each of our other currently-serving named executive officers: Mark G. Foletta, Mark J. Gergen, Orville G. Kolterman |
|
| February 25, 2011 |
Exhibit 10.27 Amylin Pharmaceuticals, Inc. 2001 Non-Qualified Deferred Compensation Plan November 15, 2010 TABLE OF CONTENTS PREAMBLE ARTICLE 1 ? GENERAL 1.1 Plan 1.2 Effective Dates 1.3 Amounts Not Subject to Code Section 409A ARTICLE 2 ? DEFINITIONS 2.1 Account 2.2 Account Balance Plan 2.3 Administrator 2.4 Adoption Agreement 2.5 Base Salary 2.6 Beneficiary 2.7 Board or Board of Directors 2.8 Bo |
|
| February 25, 2011 |
Subsidiaries of Amylin Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Amylin Pharmaceuticals, Inc. The following subsidiaries are 100% owned by Amylin Pharmaceuticals, Inc. Name State or Country of Incorporation or Organization Amylin Investments LLC Delaware Amylin Ohio LLC Delaware |
|
| February 14, 2011 |
SCHEDULE 13G Amendment No. 6 Amylin Pharmaceuticals Incorporated Common Stock Cusip #032346108 Cusip #032346108 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 10,510 Item 6: 0 Item 7: 21,584,936 Item 8: 0 Item 9: 21,584,936 Item 11: 14.990% Item 12: HC Cusip #032346108 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 21,584,9 |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NAME OF ISSUER: Amylin Pharmaceuticals, Inc. TITLE OF CLASS OF SECURITIES: Common Stock CUSIP NUMBER: 032346108 DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: December 31, 2010 Check the appropriate box to designate the rule pursuant to which this |
|
| January 26, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 26, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS 2010 FINANCIAL RESULTS 2010 Non-GAAP Operating Loss Improves by 93% to $4 Million Compared to 2009 San Diego, CA ? January 26, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2010. The Company reported total revenue of $174.2 million for the quarter ende |
|
| December 20, 2010 | ||
| December 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File |
|
| November 8, 2010 |
THIRD Amendment to Commercial Supply Agreement for Exenatide ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R ?? 200.80(b)(4) And 240.24b-2 Exhibit 10.2 CONFIDENTIAL THIRD Amendment to Commercial Supply Agreement for Exenatide THIS THIRD AMENDMENT (?Amendment?) is effective as of September 20, 2010 and is by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (?Amylin?), having a place of business at 9360 Tow |
|
| November 8, 2010 |
AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT FOR EXENATIDE Exhibit 10.1 CONFIDENTIAL AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT FOR EXENATIDE THIS AMENDMENT (?Amendment?) is effective as of April 29, 2010 and is by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (?Amylin?), having a place of business at 9360 Towne Centre Drive, San Diego, California 92121 and BACHEM, INC., a California corporation (?Bachem?), with an address of 3132 Kashiwa |
|
| November 8, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a10-17237110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0 |
|
| November 4, 2010 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Year-to-Date Non-GAAP Operating Loss of $27.3 million improves by 34% compared to 2009 San Diego, November 4, 2010 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2010. The Company reported total revenue of $156.1 million for the third |
|
| November 4, 2010 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N |
|
| October 21, 2010 |
Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N |
|
| October 21, 2010 |
Amylin Pharmaceuticals, Inc. Conference Call Held on October 19, 2010 Exhibit 99.3 Amylin Pharmaceuticals, Inc. Conference Call Held on October 19, 2010 PRESENTATION Operator Welcome to the Amylin Update. At this time, participants are in a listen-only mode until the question-and-answer session begins. (Operator Instructions.) This conference is being recorded, so if you have any objections, you may disconnect at this time. And I would like to introduce your host, M |
|
| October 21, 2010 |
AMYLIN, LILLY AND ALKERMES ANNOUNCE RECEIPT OF COMPLETE RESPONSE LETTER FROM FDA FOR BYDUREON™ Exhibit 99.2 Media contacts: Amylin ? Alice Izzo Phone: (858) 642-7272 Cell: (858) 232-9072 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] AMYLIN, LILLY AND ALKERMES ANNOUNCE RECEIPT OF COMPLETE RESPONSE LETTER FROM FDA |
|
| October 21, 2010 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Media contact: Alice Izzo Phone: (858) 642-7272 Email: [email protected] Investor Contact: Michael York Phone: (858) 458-8602 Email: [email protected] AMYLIN PHARMACEUTICALS ANNOUNCES THIRD QUARTER PRODUCT REVENUES; QUARTERLY UPDATE CONFERENCE CALL CANCELED SAN DIEGO, October 19, 2010 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that un |
|
| August 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC. |
|
| August 5, 2010 |
Exhibit 10.1 [on Amylin Letterhead] July 13, 2006 Alkermes Controlled Therapeutics Inc. II 88 Sidney Street Cambridge, MA 02139 Attn: Mike Landine Dear Mr. Landine: Amylin Pharmaceuticals, Inc. (?Amylin?) and Alkermes Controlled Therapeutics Inc. II (?ACT II?) are parties to a Development and License Agreement effective as of May 15, 2000, as amended (the ?Development and License Agreement?), purs |
|
| July 21, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 21, 2010 |
Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Year-to-Date Non-GAAP Operating Loss of $11.2 Million Improves by 74% Compared to 2009 Data Presented at ADA Further Demonstrated Safety and Efficacy Profiles of BYDUREON and BYETTA San Diego, CA — July 21, 2010 — Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the qu |
|
| June 23, 2010 | ||
| June 15, 2010 |
Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 & nbsp; Email: [email protected] DURATION-4 Study Results: BYDUREON? Efficacy and Tolerability Profi |
|
| June 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of (Commission File Number) |
|
| June 9, 2010 |
POWER OF ATTORNEY Known all by these presents, that the undersigned hereby authorizes Daniel M. |
|
| June 9, 2010 |
POWER OF ATTORNEY Known all by these presents, that the undersigned hereby authorizes Daniel M. |
|
| May 6, 2010 |
BYDUREON™ FDA REVIEW TIMELINE SET WITH PDUFA ACTION DATE OF OCTOBER 22, 2010 Exhibit 99.1 Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] BYDUREON™ FDA REVIEW TIMELINE SET WITH PDUFA ACTION DATE OF OCTOBER 22, 201 |
|
| May 6, 2010 |
AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.1 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”) (collectively, the “Award”) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceuticals, Inc. (the “Compan |
|
| May 6, 2010 |
EXHIBIT 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 [Amylin Letterhead] January 8, 2010 Mallinckrodt Inc 675 McDonnell Blvd. St. Louis, Missouri 63134 Attn: Tom Palmer Re: Exenatide Manufacturing Agreement between Amylin Pharmaceuticals, Inc. (“Amylin”) and Mallinckrodt I |
|
| May 6, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC |
|
| May 6, 2010 |
EXHIBIT 10.3 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 [Amylin Letterhead] February 11, 2010 Baxter Pharmaceutical Solutions LLC 927 South Curry Pike Bloomington, Indiana 47403 Attn: Brik Eyre Re: Commercial Supply Agreement between Baxter Pharmaceutical Solutions LLC (“Baxt |
|
| May 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Number |
|
| April 30, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Num |
|
| April 29, 2010 | ||
| April 29, 2010 | ||
| April 19, 2010 |
AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Non-GAAP Operating Loss Improves by 81% to $3.8 Million Compared to the First Quarter of 2009 BYDUREON Response to FDA Will Be Submitted This Week BYDUREON Marketing Authorization Application Submitted to the European Medicines Agency San Diego, CA — April 19, 2010 — Amylin Pharmaceuticals, Inc. (Nasd |
|
| April 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 10-K/A 1 a10-8253110ka.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commi |
|
| April 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Num |
|
| April 2, 2010 | ||
| March 19, 2010 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 15, 2010 |
Exhibit 99.1 Media contacts: Amylin — Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly — Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes — Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] AMYLIN, LILLY AND ALKERMES RECEIVE COMPLETE RESPONSE LETTER FROM FDA FOR EX |
|
| March 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Num |
|
| March 10, 2010 |
